Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Topical Corticosteroids on Insulin Sensitivity in Atopic Dermatitis
NCT04114097Phase 4Completed
- Sponsor
- LEO Pharma
- Start
- Aug 2019
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of betamethasone valerate 0.1% cream in atopic dermatitis (AD) (2 arms), sponsored by LEO Pharma. Primary endpoint: Change in whole-body insulin sensitivity at 4 weeks. Started Aug 2019; status: completed.
02
Drugs
betamethasone valerate 0.1% cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04114097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04114097.